Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Jilg, Stefanie, Hauch, Richard T., Kauschinger, Johanna, Buschhorn, Lars, Odinius, Timo O., Dill, Veronika, Müller-Thomas, Catharina, Herold, Tobias, Prodinger, Peter M., Schmidt, Burkhard, Hempel, Dirk, Bassermann, Florian, Peschel, Christian, Götze, Katharina S., Höckendorf, Ulrike, Haferlach, Torsten, Jost, Philipp J.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469098/
https://ncbi.nlm.nih.gov/pubmed/31016067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0133-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados